Bluejay Diagnostics (BJDX) Stock Price, News & Analysis

Company Overview

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting. The company has been pursuing clinical validation studies and regulatory clearances to support its plans for commercialization, working to demonstrate accuracy, reliability, and ease of use in both clinical and at-home environments.

Headquartered in Norcross, Georgia, Bluejay Diagnostics serves the U.S. market with strategic plans to expand internationally once regulatory approvals and distribution partnerships are in place. The management team brings together expertise in diagnostics, biotech development, and regulatory affairs, positioning the company to navigate the complex pathways associated with medical device registration and market entry. As Bluejay advances its development pipeline, it aims to improve patient access to timely, accurate, and patient-friendly diagnostic solutions for celiac disease and related disorders.

Key Stats

• Today's Range: $3.19 to $3.37
• 50-Day Range: $1.67 to $5.30
• 52-Week Range: $1.62 to $16.68
• Volume: 17,782 shs
• Average Volume: 790,451 shs
• Market Capitalization: $3.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Bluejay Diagnostics Stock Analysis - MarketRank™

Bluejay Diagnostics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Bluejay Diagnostics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Bluejay Diagnostics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bluejay Diagnostics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bluejay Diagnostics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bluejay Diagnostics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.23% of the float of Bluejay Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Bluejay Diagnostics has a short interest ratio ("days to cover") of 0.03, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bluejay Diagnostics has recently increased by 469.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bluejay Diagnostics does not currently pay a dividend.

Dividend Growth

Bluejay Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.44

News Sentiment

Bluejay Diagnostics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bluejay Diagnostics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for BJDX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.10% of the stock of Bluejay Diagnostics is held by insiders.

Percentage Held by Institutions

18.47% of the stock of Bluejay Diagnostics is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/26/2026
• Next Earnings (Estimated): 8/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BJDX
• CIK: 1704287
• Web: www.bluejaydx.com
• Phone: 844-327-7078
• Fax: N/A
• Employees: 9
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($11.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -144.27%
• Return on Assets: -115.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.81
• Quick Ratio: 2.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.43 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 1,030,000
• Free Float: 972,000
• Market Cap: $3.15 million
• Optionable: Not Optionable
• Beta: 0.82